ArticleStatistics in medicine2026
Design and Analysis of Randomized Clinical Trials With Average Hazard: Practical Guidance and Tools for Implementation.
Article in Statistics in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
In most randomized clinical trials evaluating intervention effects on time-to-event outcomes, the log-rank test combined with Cox's hazard ratio (HR) estimation has been the standard test/estimation approach for decades. While this traditional framework offers several advantages, concerns have been raised about HR's limitations as a summary measure of the magnitude of intervention effects. To address these concerns, an alternative approach based on the average hazard (AH) has been proposed. AH is defined as a functional of the survival function of the event time distribution and is interpreted as an average incidence rate over a given time window. Although its theoretical properties and nonparametric inference procedures have already been established, practical guidance for its use in the primary analysis of randomized clinical trials (RCTs) remains limited. In this paper, we address two key aspects critical to the implementation of AH in RCTs: (1) design considerations when the AH-based analysis is used for the primary analysis, and (2) tools for identifying the appropriate timing of the analysis. We provide a framework for study design using AH and introduce a new R package, survAHtools, to support its practical application in RCTs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.